Related references
Note: Only part of the references are listed.Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Paul Nathan et al.
CLINICAL CANCER RESEARCH (2012)
Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features: A Reproducibility Study
Kala Visvanathan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer
Andres Poveda et al.
GYNECOLOGIC ONCOLOGY (2011)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Christopher G. Przybycin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
A Phase 2 Study of the Oral Mammalian Target of Rapamycin Inhibitor, Everolimus, in Patients With Recurrent Endometrial Carcinoma
Brian M. Slomovitz et al.
CANCER (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
DNA repair deficiency as a therapeutic target in cancer
Sarah A. Martin et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
David W. Kindelberger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
Yuval Shaked et al.
SCIENCE (2006)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Jing Wang Chiang et al.
GYNECOLOGIC ONCOLOGY (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
Vascular disrupting agents: A new class of drug in cancer therapy
AM Gaya et al.
CLINICAL ONCOLOGY (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours
NLG Sieben et al.
JOURNAL OF PATHOLOGY (2004)
Vascular-targeting therapies for treatment of malignant disease
DW Siemann et al.
CANCER (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Systemic treatment policies in ovarian cancer: the next 10 years
JJ Biagi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
G Singer et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
LM Hu et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
J Sandercock et al.
BRITISH JOURNAL OF CANCER (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
C Marth et al.
CANCER (2002)
Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells
T Sudo et al.
EMBO JOURNAL (2001)
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
SD Barker et al.
GYNECOLOGIC ONCOLOGY (2001)
Cancer statistics, 2001
RT Greenlee et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2001)
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
JP Neijt et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
